Correlation Between Complete Polypoidal Regression and Visual Outcomes in Polypoidal Choroidal Vasculopathy Eyes Receiving Intravitreal Aflibercept
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Wong T, Ogura Y, Lee W, Iida T, Chen S, Mitchell P
. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study. Am J Ophthalmol. 2019; 204:80-89.
DOI: 10.1016/j.ajo.2019.02.027.
View
2.
Lim T, Lai T, Takahashi K, Wong T, Chen L, Ruamviboonsuk P
. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial. JAMA Ophthalmol. 2020; 138(9):935-942.
PMC: 7366282.
DOI: 10.1001/jamaophthalmol.2020.2443.
View
3.
Morizane-Hosokawa M, Morizane Y, Kimura S, Shiode Y, Hirano M, Doi S
. Impact of Polyp Regression on 2-year Outcomes of Intravitreal Aflibercept Injections: A Treat-and-Extend Regimen for Polypoidal Choroidal Vasculopathy. Acta Med Okayama. 2018; 72(4):379-385.
DOI: 10.18926/AMO/56175.
View
4.
Cho J, Park Y, Cho S, Ryoo N, Cho K, Park S
. POSTTREATMENT POLYP REGRESSION AND RISK OF MASSIVE SUBMACULAR HEMORRHAGE IN EYES WITH POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina. 2018; 40(3):468-476.
DOI: 10.1097/IAE.0000000000002384.
View
5.
Kimura M, Sakurada Y, Fukuda Y, Matsubara M, Kotoda Y, Kasai Y
. Association of Polyp Regression after Loading Phase with 12-Month Outcomes of Eyes with Polypoidal Choroidal Vasculopathy. Pharmaceuticals (Basel). 2024; 17(6).
PMC: 11206239.
DOI: 10.3390/ph17060687.
View